MADRID, Dec. 4, 2025 — mAbxience, a Fresenius subsidiary, and HP Inc., a worldwide technology leader, have revealed a new initiative aimed at creating an innovative artificial intelligence (AI) solution. This solution is designed to streamline the manufacturing process for monoclonal antibodies and biosimilars.
This undertaking marks a groundbreaking advancement in deploying AI within industrial biotechnology, achieved by developing a digital replica of the biological manufacturing sequence. This replica is intended to boost forecasting accuracy, uniformity, and productivity in significant production volumes. “This exemplifies technology with a clear objective: we are leveraging artificial intelligence not solely to refine procedures but to facilitate the delivery of vital therapies to a broader patient base, more rapidly and effectively,” stated Sergio Martínez, HP’s Technical Lead for this project.
In addition to its technological ingenuity, this solution offers considerable transformative benefits for all of mAbxience’s collaborators, including biosimilar licensees and CDMO customers. Through the incorporation of AI into its production activities, mAbxience seeks to substantially enhance its strategy for biologics development, improving operational performance and maximizing resource deployment. This progress will solidify the company’s standing as a dependable and economically competitive worldwide biomanufacturing provider, simultaneously aiding in improving patient availability of secure, premium biologic drugs.
“Artificial intelligence has the capacity to unlock significant, previously unexplored opportunities for optimizing biomanufacturing processes,” remarked Timo Liebig, mAbxience’s Chief Innovation Officer.
“Thanks to this partnership with HP, we have successfully created our initial prototype, which facilitates more efficient, resilient, and meticulously managed manufacturing cycles. This initiative underscores how advancements in technology can directly lead to improved patient access to crucial biologic treatments,” noted Iván Sánchez, R&D Director at mAbxience.
The development relied on actual production data, which was processed using sophisticated neural network models and verified within an industrial environment. The resulting instrument empowers mAbxience teams to simulate, examine, and refine various phases of the cell culture production sequence, aiming ultimately to boost output and minimize variations in the process.
This endeavor represents the inaugural project within the strategic partnership between HP and mAbxience, a collaboration focused on integrating AI across numerous vital departments of the company to elevate productivity, quality, and environmental responsibility across its worldwide activities. The solution, which was conceived and verified in León, also possesses the capacity for implementation across additional mAbxience facilities and operations globally.
Photo:
SOURCE mAbxience